Preclinical CRO, Animal Models & Human Antibodies

Anti-AMHR2 mAb BCG007

7E1 is a novel anti-human AMHR2 blocking antibody with desirable pharmacokinetic and pharmacodynamic properties. 7E1 may potentially find broad application for a range of cancer indications in which AMH signaling is implicated.

Download Brochure Request a Quote

on this page

Highlights of Anti-AMHR2 mAb
About AMHR2

View All

Highlights of Anti-AMHR2 mAb

Fully human Anti-AMHR2 mAbs: AMHR2 knock-out fully human RenMab mice.
Higher affinity, improved specificity and ADCC effect than Murlentamab analog.
Distinct binding epitope associated with efficient inhibition of AMH binding and signaling.
Great endocytosis activities.
PK in AMHR2-humanized mice: T1/2 > 14 days.
Superior in vivo efficacy than Murlentamab analog.
No signs of systemic toxicity.
Good Drugability.

7E1 significantly inhibits the AMH-activated signal in luciferase reporter assay

7E1 shows much longer half-life than Murlentamab analog (14.8 days vs 6.8 days)

7E1 inhibits tumor growth in hAMHR2 ID8 models in a dose-dependent manner

Treatment i.p biw*4	Tumor size on day 14	TGI_TV
Vehicle	2915±372 mm³	-
Murlentamab analog 20 mg/kg	1965±503 mm³	33.3%
7E1 10 mg/kg	1504±434 mm³	49.5%
7E1 20 mg/kg	1261±205 mm³	58.0%

About AMHR2

Ovarian cancer, comprising 85-90% of malignant gynecologic tumors, is highly prone to metastasis and has a significant mortality rate. Unfortunately, 70% of ovarian cancer patients are diagnosed in advanced stages, with most experiencing recurrence despite effective initial treatment. As such, the need for drugs to address ovarian cancer is urgent. AMHR2, a type I transmembrane protein with low-level expression in normal tissues and high expression in ovarian, cervical, and endometrial carcinomas, is an excellent potential target for broad-spectrum tumor treatment. Its ligand, AMH, induces phosphorylation of SMAD4 to activate a series of signaling pathways. Therefore, AMHR2 antibodies that promote apoptosis or directly eliminate tumor cells show great promise for treating ovarian cancer and could lead to significant clinical benefits.